|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 11/08/11 Newlink Genetics Corp S-1/A 26:5.9M Merrill Corp/New/FA |
Document/Exhibit Description Pages Size
1: S-1/A Pre-Effective Amendment to Registration Statement HTML 114K
(General Form)
2: EX-1.1 Underwriting Agreement HTML 292K
3: EX-3.2 Articles of Incorporation/Organization or By-Laws HTML 31K
4: EX-3.4 Articles of Incorporation/Organization or By-Laws HTML 223K
5: EX-5.1 Opinion re: Legality HTML 17K
6: EX-10.1 Material Contract HTML 32K
7: EX-10.10 Material Contract HTML 132K
8: EX-10.11 Material Contract HTML 70K
9: EX-10.30 Material Contract HTML 65K
10: EX-10.31 Material Contract HTML 19K
11: EX-10.32 Material Contract HTML 19K
12: EX-10.33 Material Contract HTML 113K
13: EX-10.34 Material Contract HTML 102K
14: EX-10.35 Material Contract HTML 326K
15: EX-10.36 Material Contract HTML 132K
16: EX-10.37 Material Contract HTML 311K
17: EX-10.38 Material Contract HTML 230K
18: EX-10.46 Material Contract HTML 135K
19: EX-10.47 Material Contract HTML 17K
20: EX-10.48 Material Contract HTML 17K
21: EX-10.49 Material Contract HTML 18K
22: EX-10.50 Material Contract HTML 23K
23: EX-10.66 Material Contract HTML 253K
24: EX-10.67 Material Contract HTML 401K
25: EX-10.70 Material Contract HTML 353K
26: EX-24.3 Power of Attorney HTML 65K
Exhibit 10.49
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
LICENSE AGREEMENT AMENDMENT
Inasmuch as NewLink Genetics Corporation of Ames, Iowa, and the Medical College of Georgia Research Institute of Augusta Georgia, have a valid and existing License Agreement related to the use of Indoleamine-2,3-Dioxygenase and its inhibitors in Immuno-regulation [*] dated September 13, 2005;
and
Inasmuch as the parties agree that the License Agreement contains a provision (Section 4.1) for the acquisition of new, related Improvement Technologies by NewLink arising at MCGRI after the Agreement was signed
and
Inasmuch as the NewLink has reviewed a new Improvement Technology [*], and wishes to exercise its option to incorporate this technology into the existing License Agreement technology portfolio under its standard royalty terms and use conditions,
It is Agreed:
That the parties amend the License Agreement relative to its Exhibit A , such that MCG case [*] is to be included in the technology portfolio for development and commercialization by NewLink, effective the date that the License Fee of [*] is received at MCGRI. All Payments due to the [*] will be coordinated by MCGRI according to the terms stated in [*].
This present amendment shall hereby be considered part of the original License Agreement and is hereto agreed by representatives of both parties signing below.
|
MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE |
|
|
NEWLINK GENETICS | ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By |
|
|
By: |
||
|
Name: |
|
Name: |
|||
|
Title: |
Executive Director |
|
Title: |
Chief Medical and Operations Officer | |
|
Date: |
2/13/07 |
|
|
Date: 2/6/07 | |
| This ‘S-1/A’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/8/11 | 8-A12B | ||
| 9/13/05 | ||||
| List all Filings | ||||